Lonza Group AG stock (CH0013841017): Ex-dividend date set for May 12

Lonza Group AG shareholders have until May 11 to buy shares to qualify for the upcoming 5.138 USD dividend per share, payable May 15. The stock trades ex-dividend on May 12 on Xetra and US OTC markets.

Lonza Group AG goes ex-dividend on May 12, 2026, with shareholders of record on May 13 eligible for a dividend of 5.138 USD per share, paid out on May 15, according to Deutsche Boerse as of May 11, 2026. This payout underscores Lonza's commitment to returning capital to investors amid its role in the biopharma contract development and manufacturing space.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Lonza Group AG
• Sector/industry: Biopharmaceutical contract development and manufacturing (CDMO)
• Headquarters/country: Basel, Switzerland
• Core markets: US, Europe, Asia
• Key revenue drivers: Biologics manufacturing, cell & gene therapies
• Home exchange/listing venue: SIX Swiss Exchange (LONN), OTC US (LZAGF)
• Trading currency: CHF (primary), USD (OTC)

Lonza Group AG: core business model

Lonza Group AG provides contract development and manufacturing services for biopharmaceuticals, focusing on biologics, small molecules, and advanced cell and gene therapies. The company supports clients from early-stage development through commercial-scale production, serving global pharma firms. Its facilities span Switzerland, the US, and Asia, with a strong emphasis on innovation in mRNA and viral vector technologies. Lonza's model benefits from recurring revenue as clients outsource complex manufacturing to meet regulatory standards.

For US investors, Lonza's extensive operations in the US, including sites in Texas and New Hampshire, provide direct exposure to the world's largest biopharma market. The company's role in producing key therapies positions it amid rising demand for outsourced manufacturing.

Main revenue and product drivers for Lonza Group AG

Lonza derives most revenue from its Biologics unit, which manufactures monoclonal antibodies and other proteins, followed by Capsugeling Capsules and Health Ingredients. Cell & Gene Technologies has grown rapidly, driven by demand for personalized medicines. In 2025 full-year results published March 2026, Lonza reported CHF 8.7 billion in sales, up 9% on a constant currency basis, per its IR site as of March 2026.

Key drivers include long-term contracts with major US-based clients like Moderna and Pfizer, leveraging Lonza's expertise in lipid nanoparticles and viral vectors. This segment's growth supports steady cash flows funding dividends like the upcoming payout.

Industry trends and competitive position

The CDMO sector is expanding at a 10-12% CAGR through 2030, fueled by biologics demand and capacity constraints at originators, according to S&P Global reports dated 2025. Lonza holds a top-tier position alongside Catalent and Samsung Biologics, distinguished by its end-to-end capabilities and tech investments. Recent capacity expansions in the US enhance its edge in serving North American clients.

Why Lonza Group AG matters for US investors

Lonza's OTC listing (LZAGF) offers US retail investors easy access to a Swiss blue-chip with heavy US revenue exposure—over 40% from North America. Its involvement in mRNA vaccines and gene therapies ties it to US biotech innovation hubs, providing diversification beyond domestic names while benefiting from global scale.

Conclusion

The ex-dividend date of May 12 highlights Lonza Group AG's ongoing shareholder returns amid robust biopharma demand. With strong fundamentals in high-growth segments and US market ties, the company remains a key player. Investors should monitor upcoming earnings and capacity updates for further insights into its trajectory.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.